1812 related articles for article (PubMed ID: 23526220)
21. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
22. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
Groenendijk FH; Mellema WW; van der Burg E; Schut E; Hauptmann M; Horlings HM; Willems SM; van den Heuvel MM; Jonkers J; Smit EF; Bernards R
Int J Cancer; 2015 Mar; 136(6):1434-44. PubMed ID: 25080865
[TBL] [Abstract][Full Text] [Related]
24. Stimulation of cardiomyogenesis of embryonic stem cells by nitric oxide downstream of AMP-activated protein kinase and mTOR signaling pathways.
Padmasekar M; Sharifpanah F; Finkensieper A; Wartenberg M; Sauer H
Stem Cells Dev; 2011 Dec; 20(12):2163-75. PubMed ID: 21470048
[TBL] [Abstract][Full Text] [Related]
25. AMP-activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by suppressing phosphorylation of signal transducer and activator of transcription 3 (STAT3).
Nerstedt A; Johansson A; Andersson CX; Cansby E; Smith U; Mahlapuu M
Diabetologia; 2010 Nov; 53(11):2406-16. PubMed ID: 20652679
[TBL] [Abstract][Full Text] [Related]
26. Adiponectin and metformin additively attenuate IL1β-induced malignant potential of colon cancer.
Moon HS; Mantzoros CS
Endocr Relat Cancer; 2013 Dec; 20(6):849-59. PubMed ID: 24157941
[TBL] [Abstract][Full Text] [Related]
27. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP.
Kim YD; Park KG; Lee YS; Park YY; Kim DK; Nedumaran B; Jang WG; Cho WJ; Ha J; Lee IK; Lee CH; Choi HS
Diabetes; 2008 Feb; 57(2):306-14. PubMed ID: 17909097
[TBL] [Abstract][Full Text] [Related]
28. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
29. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo.
Algire C; Amrein L; Bazile M; David S; Zakikhani M; Pollak M
Oncogene; 2011 Mar; 30(10):1174-82. PubMed ID: 21102522
[TBL] [Abstract][Full Text] [Related]
30. Activation of AMP-activated protein kinase (AMPK) mediates plumbagin-induced apoptosis and growth inhibition in cultured human colon cancer cells.
Chen MB; Zhang Y; Wei MX; Shen W; Wu XY; Yao C; Lu PH
Cell Signal; 2013 Oct; 25(10):1993-2002. PubMed ID: 23712032
[TBL] [Abstract][Full Text] [Related]
31. Anti-Tumor Activity of Yuanhuacine by Regulating AMPK/mTOR Signaling Pathway and Actin Cytoskeleton Organization in Non-Small Cell Lung Cancer Cells.
Kang JI; Hong JY; Lee HJ; Bae SY; Jung C; Park HJ; Lee SK
PLoS One; 2015; 10(12):e0144368. PubMed ID: 26656173
[TBL] [Abstract][Full Text] [Related]
32. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
Moro M; Caiola E; Ganzinelli M; Zulato E; Rulli E; Marabese M; Centonze G; Busico A; Pastorino U; de Braud FG; Vernieri C; Simbolo M; Bria E; Scarpa A; Indraccolo S; Broggini M; Sozzi G; Garassino MC
J Thorac Oncol; 2018 Nov; 13(11):1692-1704. PubMed ID: 30149143
[TBL] [Abstract][Full Text] [Related]
33. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
34. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.
Della Corte CM; Ciaramella V; Di Mauro C; Castellone MD; Papaccio F; Fasano M; Sasso FC; Martinelli E; Troiani T; De Vita F; Orditura M; Bianco R; Ciardiello F; Morgillo F
Oncotarget; 2016 Jan; 7(4):4265-78. PubMed ID: 26673006
[TBL] [Abstract][Full Text] [Related]
35. AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.
Liu JL; Mao Z; Gallick GE; Yung WK
Neuro Oncol; 2011 Feb; 13(2):184-94. PubMed ID: 21123367
[TBL] [Abstract][Full Text] [Related]
36. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
37. The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro.
Dulovic M; Jovanovic M; Xilouri M; Stefanis L; Harhaji-Trajkovic L; Kravic-Stevovic T; Paunovic V; Ardah MT; El-Agnaf OM; Kostic V; Markovic I; Trajkovic V
Neurobiol Dis; 2014 Mar; 63():1-11. PubMed ID: 24269733
[TBL] [Abstract][Full Text] [Related]
38. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
39. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.
Nagalingam A; Arbiser JL; Bonner MY; Saxena NK; Sharma D
Breast Cancer Res; 2012 Feb; 14(1):R35. PubMed ID: 22353783
[TBL] [Abstract][Full Text] [Related]
40. Silencing of the transcription factor STAT3 sensitizes lung cancer cells to DNA damaging drugs, but not to TNFα- and NK cytotoxicity.
Kulesza DW; Carré T; Chouaib S; Kaminska B
Exp Cell Res; 2013 Feb; 319(4):506-16. PubMed ID: 23149124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]